modified FOLFIRINOX + capecitabine

This neoadjuvant chemotherapy regimen is being evaluated by the Medical University of South Carolina for the treatment of localized pancreatic head adenocarcinoma. The protocol involves the administration of modified FOLFIRINOX (a combination of oxaliplatin, irinotecan, leucovorin, and fluorouracil) followed by capecitabine-based chemoradiation prior to surgical resection. Modified FOLFIRINOX works through multiple cytotoxic mechanisms: oxaliplatin acts as a platinum-based alkylating agent that forms DNA cross-links; irinotecan inhibits topoisomerase I to prevent DNA strand religation; and fluorouracil, potentiated by leucovorin, inhibits thymidylate synthase to disrupt DNA synthesis. Capecitabine, an oral prodrug of fluorouracil, is subsequently used as a radiosensitizer during concurrent radiation therapy to enhance local tumor control.

Other names

mFOLFIRINOX + capecitabineFOLFIRINOX + capecitabinemodified FOLFIRINOXmFOLFIRINOX